Fiasp (Insulin Aspart (Vials)) and Xultophy 100/3.6
Determining the interaction of Fiasp (Insulin Aspart (Vials)) and Xultophy 100/3.6 and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using liraglutide together with insulin aspart can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration of a glucagon-like peptide-1 (GLP-1) receptor agonist with insulin may potentiate the risk of hypoglycemia. GLP-1 receptor agonists lower blood glucose by stimulating insulin secretion and lowering glucagon secretion.
MANAGEMENT: When a GLP-1 receptor agonist is used as add-on therapy to basal insulin, a lower dosage of insulin may be required. Blood glucose should be monitored closely, and patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery. Concurrent use of GLP-1 receptor agonists with prandial insulin has not been studied and is generally not recommended.
- "Product Information. Ozempic (1 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Adlyxin (lixisenatide)." sanofi-aventis, Bridgewater, NJ.
- "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company, Indianapolis, IN.
- "Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline, Research Triangle Park, NC.
- "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: insulin degludec / liraglutide
Brand name: Xultophy
Synonyms: Xultophy
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fiasp (Insulin Aspart (Vials))-Xuriden
- Fiasp (Insulin Aspart (Vials))-Xylocaine
- Fiasp (Insulin Aspart (Vials))-Xylocaine (Cardiac)
- Fiasp (Insulin Aspart (Vials))-Xylocaine (Lidocaine Injection Solution (Anesthetic))
- Fiasp (Insulin Aspart (Vials))-Xylocaine (Lidocaine Oral Liquid and Solution)
- Fiasp (Insulin Aspart (Vials))-Xylocaine Dental
- Xultophy 100/3.6-Fiasp FlexTouch
- Xultophy 100/3.6-Fiasp Injection
- Xultophy 100/3.6-Fiber Lax
- Xultophy 100/3.6-Fiber Laxative
- Xultophy 100/3.6-FiberCon
- Xultophy 100/3.6-FiberGen